Loading...
Market
What will be the reduction in DUX4 regulated genes in the next AOC 1020 trial update by March 31, 2025?
5
Resolution / Starting Odds
Less than 50% • 33%
50% to 75% • 33%
More than 75% • 33%
Clinical trial updates from Avidity Biosciences
Story
Avidity Biosciences Reports Promising Phase 1/2 Data for AOC 1020 with 50% Reduction in DUX4
Jun 12, 2024, 12:26 PM
Avidity Biosciences ($RNA) announced promising results from its Phase 1/2 FORTITUDE trial for AOC 1020, targeting facioscapulohumeral muscular dystrophy (FSHD). The data showed a greater than 50 percent reduction in DUX4 regulated genes and trends of functional improvement in patients. This marks the first convincing measure of DUX4 target engagement in humans. The announcement has led to a 21.6% pre-market increase in Avidity Biosciences' stock price. Comparisons were made to Fulcrum Therapeutics' data, suggesting Avidity's drug may be more potent, though the data is at an earlier time point (16 weeks vs. 48 weeks). The results are significant for the FSHD treatment landscape, indicating potential efficacy and safety of AOC 1020. Additionally, the data derisks RWS as a more reliable endpoint for Fulcrum's upcoming readout in Q4.
View original story
Similar markets
Less than 30% • 25%
30% to 50% • 25%
51% to 70% • 25%
More than 70% • 25%
Phase 4 trial initiated • 33%
Additional Phase 3 trial initiated • 33%
No further trials announced • 33%
Less than 20% • 25%
20% to 40% • 25%
41% to 60% • 25%
More than 60% • 25%
Less than $15 • 25%
$15 to $30 • 25%
$31 to $50 • 25%
More than $50 • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Increase by 10% or more • 25%
Increase by less than 10% • 25%
No significant change • 25%
Decrease • 25%